Pharmaceutical CDMO market to grow to $90.76B by 2030 driven by peptide synthesis and biologic formulations.

The pharmaceutical contract development and manufacturing organization (CDMO) market for formulations is projected to grow from $60.7 billion in 2026 to $90.76 billion by 2030, at a CAGR of 10.6%. Growth is fueled by rising demand for custom peptide synthesis, expansion of GMP-grade production, and increased outsourcing of peptide API manufacturing. Innovations like WuXi Biologics' high-concentration biologic formulation platform and strategic acquisitions, such as Jabil's purchase of Pharmaceutics International, are enhancing manufacturing capabilities. The Asia-Pacific region leads the market, with North America expected to grow rapidly despite tariff challenges that are encouraging local production and cost efficiencies.